X

Trial Profile

Registrational study of pelareorep + paclitaxel in HR+/HER2- metastatic breast cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Pelareorep (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Registrational; Therapeutic Use

Most Recent Events

10 Oct 2024 New trial record
04 Oct 2024 According to an Oncolytics Biotech media release, the strong efficacy results from BRACELET-1 provide the foundation for a large Phase 2 study designed to support an accelerated approval. Company anticipated to Initiate registrational study of pelareorep + paclitaxel in HR+/HER2- metastatic breast cancer in H1 2025.
04 Oct 2024 According to Oncolytics Biotech media release, enrollment in the registration-enabling study is expected to commence in the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com